THERAPEUTIC AREA
saveImmunology
Immune-mediated and autoimmune disorders.
also known as: immune, autoimmune, i and i
🐶 often sniffed alongside
top 8- drugImmunology80 co-mentions · 76 sources
- tag510(k) Clearance27 co-mentions · 27 sources
- tagAdCom27 co-mentions · 27 sources
- tagPsoriasis14 co-mentions · 4 sources
- tagPain14 co-mentions · 3 sources
- tagDiagnostics Company12 co-mentions · 12 sources
- tagLupus11 co-mentions · 6 sources
- tagOncology10 co-mentions · 9 sources
drugs
371
catalysts
35
news
2,150
companies
269
Top drugs
view all →Marketed
adrenaline
Hypotension
113 catalysts
Marketedadalimumab
Intermediate Uveitis
$ABBV · 61 catalysts
Marketedtocilizumab
Coronavirus Disease 2019 (COVID-19)
61 catalysts
Marketedmethylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
MarketedMETHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
Marketedcertolizumab pegol
Ankylosing Spondylitis (Bekhterev's Disease)
35 catalysts
MarketedMEDROL
$PFE · 34 catalysts
Marketedtofacitinib citrate ER
Ankylosing Spondylitis (Bekhterev's Disease)
32 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Sunstar Inc — SSJG-009 (Phase II Trial Completion)
SSJG-009
→
Apr 30, 2026
phase 2 completion
Renji Hospital — norepinephrine (Phase II Trial Completion)
norepinephrine
→
Apr 30, 2026
phase 2 completion
Nigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)
ozonated oil
→
Apr 30, 2026
phase 2 completion
$MRK144.30+0.34%
Merck & Co Inc — tulisokibart (Phase II Trial Completion)
tulisokibart
→
Apr 30, 2026
phase 2 completion
Guy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)
autologous regulatory T cells
→
Apr 30, 2026
phase 2 completion
Zhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)
telitacicept
→
Apr 30, 2026
phase 2 completion
Usynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)
UA-021
→
Apr 30, 2026
phase 1 initiation
Nanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)
IASO-782
→
Apr 30, 2026
phase 1 completion
Insignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)
HLK-0006
→
Apr 30, 2026
phase 1 completion
Avance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)
FT-2109
→
Recent news
view all →- STAT+: Hospital and pharmaceutical prices are smothering America’s businessesstat · 3h ago
- STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questionsstat · 3h ago
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketbiospace · 7h ago
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketbiospace · 7h ago
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drugfiercebiotech · 7h ago
- Roivant, the 'inveterate drug hunters', enters commercial era with Lisrayabiospace · 8h ago
- Swiss CDMOs and CROs ride a new wave of growth amid surge in global demandbiospace · 8h ago
- EAK Distribution LLC Recalls HOME GROWN Green Sprouting Calabrese Broccoli Seeds, 8 oz, Heirloom Because of Possible Health Riskfda recalls · 2d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that